...
首页> 外文期刊>Annals of surgical oncology >Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma
【24h】

Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma

机译:原发性上尿路尿路上皮癌患者行根治性肾切除术后膀胱内复发治疗后膀胱结局的独立预测因子

获取原文
获取原文并翻译 | 示例
           

摘要

Background. Few studies have described the clinical courses and outcomes in the bladder after treatment of intravesical recurrence after radical nephroureterectomy (RNU) in patients with primary upper tract urothelial carcinoma (UTUC). We investigated the indicators for predicting subsequent bladder outcomes after treatment of intravesical recurrence after RNU. Methods. A total of 241 patients with primary UTUC (pTa-4N0M0) who experienced intravesical recurrence after RNU were included. Of these patients, 101 (41.9 %) underwent Bacillus Calmette-Guérin treatments, whereas 49 (20.3 %) underwent intravesical chemotherapy. The median follow-up period after initial transurethral resection of the bladder tumor was 33 months. Relationships with bladder outcomes were analyzed by using multivariable analysis. Results. Ninety-six patients experienced intravesical recurrence, and bladder progression was observed in 13. Cumulative incidence rates of intravesical recurrence at 1 and 5 years after treatment of the first intravesical recurrence were 31.0 and 48.4 %, whereas those of bladder progression at 1 and 5 years thereafter were 2.4 and 8.0 %. Multivariate analysis showed that the number of recurrent tumors and pT1 tumors at the time of the first intravesical relapse were independent risk factors for subsequent intravesical recurrence. With respect to bladder progression, multivariate analysis showed that pT1 tumors, the appearance of concomitant carcinoma-in situ at the time of the first intravesical relapse, and the absence of the Bacillus Calmette-Guérin treatment were independent risk factors. Conclusions. This retrospective study presents a detailed picture of further bladder outcomes after intravesical recurrence after RNU in primary UTUC patients. The results may assist physicians to develop a more rational protocol in bladder surveillance.
机译:背景。很少有研究描述原发性上尿路尿路上皮癌(UTUC)患者行根治性肾切除术后(RNU)膀胱内复发治疗后膀胱的临床过程和结果。我们调查了RNU后膀胱内复发治疗后预测随后膀胱结局的指标。方法。纳入总共241例RNU术后膀胱内复发的原发性UTUC(pTa-4N0M0)患者。在这些患者中,有101例(41.9%)接受了Calmette-Guérin芽孢杆菌治疗,而49例(20.3%)接受了膀胱内化疗。首次经尿道膀胱肿瘤切除后的中位随访期为33个月。与膀胱结局的关系通过多变量分析进行了分析。结果。九十六例患者经历了膀胱内复发,并且在13例中观察到了膀胱进展。首次膀胱内复发治疗后1年和5年,膀胱内复发的累积发生率分别为31.0和48.4%,而在1年和5年时膀胱进展的累积发生率此后分别为2.4%和8.0%。多因素分析表明,首次膀胱内复发时复发肿瘤和pT1肿瘤的数量是随后膀胱内复发的独立危险因素。关于膀胱进展,多因素分析显示,pT1肿瘤,首次膀胱内复发时原位癌的出现以及卡介苗的治疗均是独立的危险因素。结论这项回顾性研究提供了原发性UTUC患者RNU膀胱内复发后膀胱进一步结局的详细情况。该结果可能有助于医师制定更合理的膀胱监测方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号